Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Johnson & Johnson ( (JNJ) ) has provided an update.
On September 8, 2025, Johnson & Johnson announced the election of John Morikis, former Executive Chairman, President, and CEO of The Sherwin-Williams Company, to its Board of Directors. Morikis, recognized for his leadership in global markets and supply chains, will contribute to Johnson & Johnson’s long-term strategy of healthcare innovation and shareholder value creation.
The most recent analyst rating on (JNJ) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Johnson & Johnson stock, see the JNJ Stock Forecast page.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
Johnson & Johnson receives a solid overall score of 77.8, driven primarily by its strong financial performance and positive earnings call. The company’s robust margins, steady growth, and raised guidance indicate a positive outlook, while technical indicators suggest short-term caution due to potential overbought conditions. Valuation metrics further support the stock’s attractiveness, offering an appealing dividend yield.
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
Johnson & Johnson is a leader in healthcare innovation, focusing on preventing, treating, and curing complex diseases. The company leverages its expertise in Innovative Medicine and MedTech to provide smarter, less invasive treatments and personalized solutions, aiming to deliver significant healthcare breakthroughs.
Average Trading Volume: 8,476,615
Technical Sentiment Signal: Buy
Current Market Cap: $429.7B
See more data about JNJ stock on TipRanks’ Stock Analysis page.